A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences
- 18 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 133 (3), 949-958
- https://doi.org/10.1007/s10549-011-1856-9
Abstract
Male breast cancer remains understudied despite evidence of rising incidence. Using a co-ordinated multi-centre approach, we present the first large scale biomarker study to define and compare hormone receptor profiles and survival between male and female invasive breast cancer. We defined and compared hormone receptor profiles and survival between 251 male and 263 female breast cancers matched for grade, age, and lymph node status. Tissue microarrays were immunostained for ERα, ERβ1, -2, -5, PR, PRA, PRB and AR, augmented by HER2, CK5/6, 14, 18 and 19 to assist typing. Hierarchical clustering determined differential nature of influences between genders. Luminal A was the most common phenotype in both sexes. Luminal B and HER2 were not seen in males. Basal phenotype was infrequent in both. No differences in overall survival at 5 or 10 years were observed between genders. Notably, AR-positive luminal A male breast cancer had improved overall survival over female breast cancer at 5 (P = 0.01, HR = 0.39, 95% CI = 0.26–0.87) but not 10 years (P = 0.29, HR = 0.75, 95% CI = 0.46–1.26) and both 5 (P = 0.04, HR = 0.37, 95% CI = 0.07–0.97) and 10 years (P = 0.04, HR = 0.43, 95% CI = 0.12–0.97) in the unselected group. Hierarchical clustering revealed common clusters between genders including total PR–PRA–PRB and ERβ1/2 clusters. A striking feature was the occurrence of ERα on distinct clusters between genders. In female breast cancer, ERα clustered with PR and its isoforms; in male breast cancer, ERα clustered with ERβ isoforms and AR. Our data supports the hypothesis that breast cancer is biologically different in males and females suggesting implications for clinical management. With the incidence of male breast cancer increasing this provides impetus for further study.Keywords
This publication has 56 references indexed in Scilit:
- Mutations in BRCA2 and PALB2 in male breast cancer cases from the United StatesBreast Cancer Research and Treatment, 2010
- Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancerBreast Cancer Research and Treatment, 2010
- Estrogen Receptor β1 Expression Is Regulated by miR-92 in Breast CancerCancer Research, 2010
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI Journal of the National Cancer Institute, 2009
- Clinical Importance of Estrogen Receptor-β Evaluation in Breast Cancer Patients Treated With Adjuvant Tamoxifen TherapyJournal of Clinical Oncology, 2008
- Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 casesVirchows Archiv, 2006
- Male breast cancerThe Lancet, 2006
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005
- Breast carcinoma in menCancer, 2004
- Is Male Breast Cancer Similar or Different than Female Breast Cancer?Breast Cancer Research and Treatment, 2004